MCID: HRT032
MIFTS: 84

Heart Disease

Categories: Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Heart Disease

MalaCards integrated aliases for Heart Disease:

Name: Heart Disease 12 6 15 17
Congenital Heart Disease 12 29 54 6 15 17 70
Heart Failure 54 6 42 62 17 70 32
Congenital Heart Defects 12 29 6 42 3 62
Heart Diseases 54 42 44 15 70
Congenital Heart Defect 12 6
Heart Defect 12 6
Congenital Anomaly of Heart 12
Disease, Heart, Congenital 39
Congenital Heart Disorder 73
Heart Defects, Congenital 44
Heart Disease, Congenital 39
Congestive Heart Failure 70
Heart Defects Congenital 54
Abnormality of the Heart 6
Heart-Congenital Defect 12
Heart Malformation 12
Heart Defects 15

Classifications:



External Ids:

Disease Ontology 12 DOID:114 DOID:1682
ICD9CM 34 429.9 746.9
NCIt 50 C3079 C34666
SNOMED-CT 67 194707003 268315002
UMLS 70 C0018798 C0018799 C0018801 more

Summaries for Heart Disease

MedlinePlus : 42 If you're like most people, you think that heart disease is a problem for others. But heart disease is the number one killer in the U.S. It is also a major cause of disability. There are many different forms of heart disease. The most common cause of heart disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself. This is called coronary artery disease and happens slowly over time. It's the major reason people have heart attacks. Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure. Some people are born with heart disease. You can help reduce your risk of heart disease by taking steps to control factors that put you at greater risk: Control your blood pressure Lower your cholesterol Don't smoke Get enough exercise NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Disease, also known as congenital heart disease, is related to heart valve disease and lipoprotein quantitative trait locus, and has symptoms including tremor, angina pectoris and chest pain. An important gene associated with Heart Disease is NKX2-5 (NK2 Homeobox 5), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and NFAT and Cardiac Hypertrophy. The drugs Thalidomide and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and bone marrow, and related phenotypes are cardiovascular system and growth/size/body region

CDC : 3 Congenital heart defects (CHDs) are conditions that are present at birth and can affect the structure of a baby's heart and the way it works. They are the most common type of birth defect. As medical care and treatment have advanced, infants with congenital heart defects are living longer and healthier lives. Many now are living into adulthood.

PubMed Health : 62 About congenital heart defects: Congenital (kon-JEN-ih-tal) heart defects are problems with the heart's structure that are present at birth. These defects can involve:

Wikipedia : 73 A congenital heart defect (CHD), also known as a congenital heart anomaly and congenital heart disease,... more...

Related Diseases for Heart Disease

Diseases in the Heart Disease family:

Congenital Heart Defects, Multiple Types, 6 Congenital Heart Defects, Multiple Types, 3
Congenital Heart Defects, Multiple Types, 2 Congenital Heart Defects, Multiple Types, 4
Congenital Heart Defects, Multiple Types, 5 Congenital Heart Defects, Multiple Types, 7

Diseases related to Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2790)
# Related Disease Score Top Affiliating Genes
1 heart valve disease 33.3 NKX2-5 MYH6 MIR21
2 lipoprotein quantitative trait locus 33.3 TEK TBX5 NKX2-5 MYH6 MIR21 GATA4
3 ventricular septal defect 33.3 TBX5 NODAL NKX2-5 JAG1 GATA6 GATA4
4 heart septal defect 33.3 TBX5 PTPN11 NODAL NKX2-5 MYH6 JAG1
5 patent ductus arteriosus 1 33.3 TBX5 PTPN11 NODAL NKX2-5 MYH6 JAG1
6 tetralogy of fallot 33.2 TBX5 PTPN11 NODAL NKX2-5 MYH6 JAG1
7 aortic valve disease 1 33.1 TBX5 NKX2-5 MYH6 MIR21 JAG1 GATA6
8 hypoplastic left heart syndrome 33.1 TBX5 NODAL NKX2-5 MYH6 JAG1 GATA6
9 dilated cardiomyopathy 33.1 TBX5 PTPN11 NKX2-5 MYH6 MAPK1 GATA6
10 atrial heart septal defect 33.0 TBX5 PTPN11 NODAL NKX2-5 MYH6 JAG1
11 double outlet right ventricle 32.9 TBX5 NODAL NKX2-5 MYH6 GATA6 GATA4
12 dextro-looped transposition of the great arteries 32.9 TBX5 NODAL NKX2-5 GATA4
13 tricuspid atresia 32.7 TBX5 NKX2-5 GATA6 GATA4
14 total anomalous pulmonary venous return 1 32.6 TBX5 NODAL NKX2-5 GATA4
15 wolff-parkinson-white syndrome 32.6 NODAL NKX2-5 MYH6 JAG1
16 hypertrophic cardiomyopathy 32.5 PTPN11 NKX2-5 MYH6 MIR21 GATA6 GATA4
17 atrioventricular septal defect 32.4 TBX5 NODAL NKX2-5 MYH6 GATA6 GATA4
18 patent foramen ovale 32.3 TBX5 PTPN11 NKX2-5 MYH6 GATA6 GATA4
19 pulmonary valve stenosis 32.2 TBX5 PTPN11 NKX2-5 JAG1 GATA4
20 atrioventricular block 32.2 TBX5 NKX2-5 GATA4
21 aortic valve disease 2 32.2 TBX5 NKX2-5 MYH6 MIR21 GATA4
22 hypoplastic right heart syndrome 32.0 TBX5 NKX2-5
23 ebstein anomaly 32.0 TBX5 NODAL NKX2-5 MYH6 GATA4 CDK8
24 tricuspid valve disease 32.0 TBX5 NKX2-5 MYH6 GATA6 GATA4
25 pulmonary valve disease 31.9 TBX5 PTPN11 NKX2-5 GATA6 GATA4
26 interatrial communication 31.8 TBX5 NKX2-5 MYH6 GATA6 GATA4
27 left ventricular noncompaction 31.7 TBX5 PTEN NKX2-5 MYH6 JAG1 GATA4
28 sinoatrial node disease 31.6 TBX5 NKX2-5 MYH6
29 holt-oram syndrome 31.5 TBX5 NKX2-5 MYH6 GATA4
30 right atrial isomerism 31.3 TBX5 NODAL NKX2-5
31 atrial septal defect 2 31.3 TBX5 PTPN11 NKX2-5 GATA4
32 diaphragmatic hernia, congenital 31.3 TBX5 GATA6 GATA4 CDK8
33 rasopathy 31.1 TBX5 PTPN11 PTEN PIK3CA NKX2-5 MYH6
34 noonan syndrome with multiple lentigines 31.1 TBX5 PTPN11 NKX2-5 MYH6 GATA4
35 partial atrioventricular canal 30.9 GATA6 GATA4
36 alagille syndrome 1 30.9 TBX5 NKX2-5 JAG1
37 atypical coarctation of aorta 30.9 JAG1 GATA6
38 leukemia, acute myeloid 30.8 TEK PTPN11 PTEN PIK3CA MIR320A MIR210
39 limb ischemia 30.8 TEK MIR210 MIR21
40 intrinsic cardiomyopathy 30.7 NKX2-5 MYH6 MIR21 GATA4
41 congenital heart defects, multiple types, 4 30.7 GATA6 GATA4
42 leukemia, acute lymphoblastic 30.6 PTPN11 PTEN MIR210 MIR21 ABL1
43 hemangioma 30.6 TEK PTEN JAG1 GNAQ
44 klippel-trenaunay-weber syndrome 30.5 TEK PIK3CA GNAQ
45 jacobsen syndrome 30.5 TBX5 NKX2-5 GATA4
46 heart, malformation of 30.5 TBX5 NODAL MAPK1 JAG1 CDK8 BRF1
47 cholangiocarcinoma 30.3 PIK3CA MIR320A MIR21 MAPK1
48 abnormal hair, joint laxity, and developmental delay 30.2 PTPN11 JAG1
49 kidney cancer 30.2 PTEN PIK3CA MIR210 MIR21
50 diffuse large b-cell lymphoma 30.1 PTEN MIR320A MIR210 MIR21

Comorbidity relations with Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 316)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Accessory Nerve Disease
Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Anterolateral Myocardial Infarction
Acute Apical Periodontitis Acute Conjunctivitis
Acute Cor Pulmonale Acute Cystitis
Acute Inferolateral Myocardial Infarction Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Myocarditis Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Age-Related Hearing Loss Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Allergic Urticaria
Alzheimer Disease Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Aspergillosis
Asthma Atrial Standstill 1
Atrioventricular Block Atrophic Gastritis
Bacteremia 2 Balanoposthitis
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Renovascular Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Blepharoconjunctivitis Bronchiectasis
Bronchitis Bronchopneumonia

Graphical network of the top 20 diseases related to Heart Disease:



Diseases related to Heart Disease

Symptoms & Phenotypes for Heart Disease

UMLS symptoms related to Heart Disease:


tremor; angina pectoris; chest pain; syncope; edema; equilibration disorder

MGI Mouse Phenotypes related to Heart Disease:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 ABL1 CDK8 GATA4 GATA6 GNAQ JAG1
2 growth/size/body region MP:0005378 10.44 ABL1 BBS12 BRF1 CDK8 GATA4 GATA6
3 homeostasis/metabolism MP:0005376 10.42 ABL1 BBS12 BRF1 CDK8 GATA4 GATA6
4 cellular MP:0005384 10.41 ABL1 BBS12 BRF1 CDK8 GATA4 GATA6
5 embryo MP:0005380 10.38 ABL1 BRF1 CDK8 GATA4 GATA6 JAG1
6 mortality/aging MP:0010768 10.31 ABL1 BRF1 CDK8 GATA4 GATA6 GNAQ
7 endocrine/exocrine gland MP:0005379 10.26 ABL1 BRF1 CDK8 GATA4 GNAQ JAG1
8 muscle MP:0005369 10.21 ABL1 GATA4 GATA6 GNAQ JAG1 MAPK1
9 craniofacial MP:0005382 10.16 ABL1 CDK8 GNAQ JAG1 MAPK1 NKX2-5
10 digestive/alimentary MP:0005381 10.15 ABL1 GATA4 JAG1 MAPK1 NKX2-5 NODAL
11 integument MP:0010771 10.13 GATA4 GNAQ JAG1 MAPK1 NKX2-5 PIK3CA
12 liver/biliary system MP:0005370 10.13 ABL1 BRF1 GATA4 GATA6 JAG1 MAPK1
13 nervous system MP:0003631 10.13 ABL1 BBS12 CDK8 GATA4 GNAQ JAG1
14 limbs/digits/tail MP:0005371 10 CDK8 GATA4 GATA6 GNAQ PTEN PTPN11
15 normal MP:0002873 10 ABL1 GATA4 GATA6 GNAQ JAG1 NKX2-5
16 respiratory system MP:0005388 9.85 ABL1 GATA4 GATA6 GNAQ MAPK1 MYH6
17 skeleton MP:0005390 9.7 ABL1 BBS12 GATA4 GNAQ JAG1 MAPK1
18 vision/eye MP:0005391 9.28 ABL1 BBS12 JAG1 MAPK1 NODAL PIK3CA

Drugs & Therapeutics for Heart Disease

PubMed Health treatment related to Heart Disease: 62

Although many children who have congenital heart defects don't need treatment , some do. Doctors repair congenital heart defects with catheter procedures or surgery . Sometimes doctors combine catheter and surgical procedures to repair complex heart defects, which may involve several kinds of defects. The treatment your child receives depends on the type and severity of his or her heart defect. Other factors include your child's age, size, and general health. Some children who have complex congenital heart defects may need several catheter or surgical procedures over a period of years, or they may need to take medicines for years.

Drugs for Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 913)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56329 56330
4
Spirapril Approved Phase 4 83647-97-6 5311447
5
Zofenopril Approved Phase 4 81872-10-8
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
8
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
9
Budesonide Approved Phase 4 51333-22-3 63006 5281004
10
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
11 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
12
Warfarin Approved Phase 4 81-81-2 6691 54678486
13
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
14
Zolpidem Approved Phase 4 82626-48-0 5732
15
Promethazine Approved, Investigational Phase 4 60-87-7 4927
16
Pantoprazole Approved Phase 4 102625-70-7 4679
17
Atorvastatin Approved Phase 4 134523-00-5 60823
18
Allopurinol Approved Phase 4 315-30-0 2094
19
Chlorthalidone Approved Phase 4 77-36-1 2732
20
Vancomycin Approved Phase 4 1404-90-6 441141 14969
21
Metformin Approved Phase 4 657-24-9 14219 4091
22
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
23
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
24
Methyltestosterone Approved Phase 4 58-18-4 6010
25
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
26
Testosterone enanthate Approved Phase 4 315-37-7 9416
27
Testosterone Approved, Investigational Phase 4 58-22-0 6013
28
Magnesium oxide Approved Phase 4 1309-48-4 14792
29
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
30
Ramipril Approved Phase 4 87333-19-5 5362129
31
Captopril Approved Phase 4 62571-86-2 44093
32
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
33
Alogliptin Approved Phase 4 850649-61-5 11450633
34
Saxagliptin Approved Phase 4 361442-04-8 11243969
35
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
36
Linagliptin Approved Phase 4 668270-12-0 10096344
37
Cefazolin Approved Phase 4 25953-19-9 656510 33255
38
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
39
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
40
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
41
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
42
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
43
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
44
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
45
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
46
Atenolol Approved Phase 4 29122-68-7 2249
47
Trandolapril Approved Phase 4 87679-37-6 5484727
48
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
49
Fenofibrate Approved Phase 4 49562-28-9 3339
50
Acarbose Approved, Investigational Phase 4 56180-94-0 441184

Interventional clinical trials:

(show top 50) (show all 7518)
# Name Status NCT ID Phase Drugs
1 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
2 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
3 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
4 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
5 Effect of Sevoflurane Anesthesia in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery: a Randomized Controlled Clinical Trial Unknown status NCT03630796 Phase 4 Sevoflurane;TIVA
6 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
7 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study Unknown status NCT00552851 Phase 4 pegvisomant
8 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
9 The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial Unknown status NCT01942109 Phase 4 Furosemide;Torasemide
10 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
11 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Unknown status NCT03096613 Phase 4 Levothyroxine
12 A Randomized, Controlled Trial Evaluating Efficacy of Perioperative Organ Protection as Well as Safety of Ulinastatin Use in Pediatric Patients Undergoing Open Heart Surgery Through CPB to Treat Complex Congenital Heart Diseases Unknown status NCT02527811 Phase 4 Ulinastatin
13 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
14 The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial. Unknown status NCT02299063 Phase 4 Dexmedetomidine;0.9% NaCl
15 Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure Unknown status NCT00988806 Phase 4 Levosimendan;Placebo
16 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
17 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
18 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
19 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
20 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
21 A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS. Unknown status NCT01918150 Phase 4
22 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
23 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
24 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
25 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
26 NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial Unknown status NCT02817360 Phase 4 RAS-antagonist and beta-blocker up-to maximal dosages
27 Observational Study of Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery Unknown status NCT01457586 Phase 4
28 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
29 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
30 Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) Unknown status NCT03486561 Phase 4 Ranolazine
31 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
32 Optimal Dose of Ticagrelor(90 mg qd)and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease Unknown status NCT03614832 Phase 4 Ticagrelor 90 mg;Clopidogrel 150 mg
33 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
34 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
35 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
36 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
37 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
38 Cardiac Metabolic Modulator Treatment for Improvement of Left Ventricular Diastolic Function in Patients With Coronary Heart Disease: a Prospective, Randomized Controlled Study Unknown status NCT03887013 Phase 4 Trimetazidine
39 A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus Unknown status NCT03159559 Phase 4 Lipo-PGE1
40 Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
41 Randomized Comparison of Outcome of Stenting in Unselected Patients in Everyday Clinical Practice Unknown status NCT01534221 Phase 4
42 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
43 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
44 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
45 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
46 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
47 High Dose Versus Low Dose Heparinization in Patients Undergoing Offpump Coronary Artery Bypass Unknown status NCT02812355 Phase 4 Heparin
48 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
49 The Diagnostic Benefits of HyperQTM vs. Conventional ECG During Stress Test. A Comparison Study in Women Referred to Angiography. Unknown status NCT00850486 Phase 4
50 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4

Search NIH Clinical Center for Heart Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Atenolol
benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Captopril
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
coenzyme Q10
cyclothiazide
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam
Fenoldopam Mesylate
Fosinopril
Fosinopril Sodium
Furosemide
Growth Hormone
Hydralazine
Hydralazine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Inamrinone
inamrinone lactate
Indapamide
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol
Labetalol hydrochloride
Lisinopril
Losartan
Losartan Potassium
Methyclothiazide
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Milrinone
Milrinone Lactate
moexipril
Moexipril hydrochloride
Nadolol
Nitroglycerin
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
Polythiazide
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Sodium Nitroprusside
somatrem
Somatropin
SOMATROPIN (RECOMBINANT DNA ORIGIN)
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Trichlormethiazide
valsartan

Cochrane evidence based reviews: heart diseases

Genetic Tests for Heart Disease

Genetic tests related to Heart Disease:

# Genetic test Affiliating Genes
1 Congenital Heart Disease 29
2 Congenital Heart Defects 29

Anatomical Context for Heart Disease

MalaCards organs/tissues related to Heart Disease:

40
Heart, Endothelial, Bone Marrow, Bone, Kidney, Thyroid, Liver

Publications for Heart Disease

Articles related to Heart Disease:

(show top 50) (show all 62210)
# Title Authors PMID Year
1
Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. 54 6
10587520 1999
2
Age dependent associations of risk factors with heart failure: pooled population based cohort study. 42 61
33758001 2021
3
His bundle pacing therapy for patients with chronic heart failure: A protocol for meta-analysis based on prospective studies. 42 61
33761667 2021
4
Associations of maternal diabetes mellitus and adiponectin gene polymorphisms with congenital heart disease in offspring: A case-control study. 61 42
33655931 2021
5
Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. 6
30712880 2019
6
De novo variants in congenital diaphragmatic hernia identify MYRF as a new syndrome and reveal genetic overlaps with other developmental disorders. 6
30532227 2018
7
Prenatal diagnosis of short-rib polydactyly syndrome type III or short-rib thoracic dysplasia 3 with or without polydactyly (SRTD3) associated with compound heterozygous mutations in DYNC2H1 in a fetus. 6
29458881 2018
8
Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformations. 6
28288113 2017
9
Congenital heart diseases and their association with the variant distribution features on susceptibility genes. 6
27426723 2017
10
Congenital heart defects and left ventricular non-compaction in males with loss-of-function variants in NONO. 6
27550220 2017
11
A homozygous truncating mutation in PUS3 expands the role of tRNA modification in normal cognition. 6
27055666 2016
12
Mutations in SMG9, Encoding an Essential Component of Nonsense-Mediated Decay Machinery, Cause a Multiple Congenital Anomaly Syndrome in Humans and Mice. 6
27018474 2016
13
Affected kindred analysis of human X chromosome exomes to identify novel X-linked intellectual disability genes. 6
25679214 2015
14
Whole exome sequencing identifies de novo mutations in GATA6 associated with congenital diaphragmatic hernia. 6
24385578 2014
15
Dominant and recessive forms of fibrochondrogenesis resulting from mutations at a second locus, COL11A2. 6
22246659 2012
16
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. 61 47
20837903 2010
17
Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. 47 61
19514064 2009
18
Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. 6
19064609 2009
19
Twelve novel JAG1 gene mutations in Polish Alagille syndrome patients. 6
15712272 2005
20
DHPLC mutation analysis of Jagged1 (JAG1) reveals six novel mutations in Australian alagille syndrome patients. 6
12442286 2002
21
Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome. 6
10220506 1999
22
Congenital heart disease caused by mutations in the transcription factor NKX2-5. 6
9651244 1998
23
Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. 6
9207788 1997
24
Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis. 42
33725910 2021
25
Fate of the Arterial Origin of Major Aortopulmonary Collateral Arteries After Unifocalization. 42
33684007 2021
26
Pre-operative echocardiograms in acute fragility hip fractures: How effective are the guidelines? 42
33761684 2021
27
Safe Operation of an Echocardiography Practice During the COVID-19 Pandemic: Single-Center Experience. 42
33673905 2021
28
Maternal fever during preconception and conception is associated with congenital heart diseases in offspring: An updated meta-analysis of observational studies. 42
33655950 2021
29
Interventions related to cardiovascular complications in people hospitalized by covid-19: a scoping review. 42
33566953 2021
30
MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. 47
20837890 2010
31
Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. 61 54
20233990 2010
32
Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. 61 54
20211335 2010
33
[Novel GATA4 mutations identified in patients with congenital heart disease]. 54 61
20450724 2010
34
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction. 54 61
20391898 2010
35
[Correlation between left ventricular diastolic function and plasma natriuretic peptide level in children with pulmonary artery hypertension secondary to congenital heart disease]. 61 54
20113626 2010
36
[Polymorphism of eNOS and iNOS Genes and Chronic Heart Failure in Patients With Ischemic Heart Disease]. 54 61
20459417 2010
37
[Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease]. 54 61
19558803 2009
38
MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. 47
19380620 2009
39
[The mechanism of TBX5 abnormal expression in simple congenital heart disease]. 54 61
19586889 2009
40
Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). 61 54
19165564 2009
41
[N-terminal fragment of the brain natriuretic peptide and proinflammatory cytokines in patients with ischemic heart disease]. 61 54
19537583 2009
42
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. 47
19043405 2008
43
GATA4 mutations in 486 Chinese patients with congenital heart disease. 61 54
18672102 2008
44
Urocortins in heart failure and ischemic heart disease. 54 61
18180061 2008
45
Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. 61 54
18158473 2008
46
[Pathophysiology of heart failure and the biomarkers; brain natriuretic hormone as the class-1 recommendation by the new Japanese Guideline for Heart Failure]. 54 61
18283862 2007
47
[Diagnostic and prognostic value of B-type natriuretic peptides in heart failure or signs of heart failure]. 61 54
18074722 2007
48
[Changes of the levels of adrenomedulin, endothelin-1 and nitric oxide in children with pulmonary hypertension secondary to congenital heart disease]. 54 61
18211765 2007
49
Ryanodine receptor: a novel therapeutic target in heart disease. 61 54
18221109 2007
50
Serum resistin is associated with high risk in patients with congestive heart failure--a novel link between metabolic signals and heart failure. 54 61
17384443 2007